A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Authors
Keywords
Clear cell renal cell carcinoma, Immune checkpoint inhibition, PD-1, PD-L1, Immunohistochemistry, Sampling protocols, Targeted therapy
Journal
Current Urology Reports
Volume 20, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-15
DOI
10.1007/s11934-019-0866-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs
- (2018) Enrico Munari et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma
- (2018) Rosa Guarch et al. Annals of Diagnostic Pathology
- Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma
- (2018) José I. López et al. Annals of Diagnostic Pathology
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
- (2018) Michael B. Atkins et al. CANCER TREATMENT REVIEWS
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals
- (2018) Zhun Wang et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
- (2018) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
- (2018) Shona Hendry et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
- (2018) José I. López et al. PATHOLOGY RESEARCH AND PRACTICE
- The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer
- (2018) Jiayu Liang et al. Scientific Reports
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
- (2018) Hayriye Tatli Dogan et al. Diagnostic Pathology
- Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types
- (2018) Chiyun Wang et al. HUMAN PATHOLOGY
- Kidney cancer: The next decade
- (2018) Samra Turajlic et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
- (2018) Han Yao et al. Frontiers in Immunology
- Contemporary Management of 1–4 Brain Metastases
- (2018) Sarah M. C. Sittenfeld et al. Frontiers in Oncology
- Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection
- (2017) José I. López et al. HUMAN PATHOLOGY
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis
- (2017) Tomohiro F. Nishijima et al. ONCOLOGIST
- Molecular heterogeneity in breast cancer: State of the science and implications for patient care
- (2017) Rachel E. Ellsworth et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
- (2017) Henrick Horita et al. NEOPLASIA
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status
- (2016) Yosra Messai et al. EUROPEAN UROLOGY
- Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)
- (2016) Michael B. Atkins et al. EXPERT OPINION ON EMERGING DRUGS
- PD-1/PD-L1 blockade in renal cell cancer
- (2016) Kathryn E. Beckermann et al. Expert Review of Clinical Immunology
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential
- (2016) Solène-Florence Kammerer-Jacquet et al. INTERNATIONAL JOURNAL OF CANCER
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
- (2016) M. Abbas et al. MEDICAL ONCOLOGY
- Systemic therapy in metastatic renal cell carcinoma
- (2016) Jens Bedke et al. WORLD JOURNAL OF UROLOGY
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma
- (2016) M. L. Ascierto et al. Cancer Immunology Research
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
- (2015) Su-Jin Shin et al. ANNALS OF SURGICAL ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma
- (2015) Yiwei Wang et al. MEDICAL ONCOLOGY
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous
- (2014) Laura Zaldumbide et al. VIRCHOWS ARCHIV
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
- (2014) L.B. Jilaveanu et al. Journal of Cancer
- IMA901: a peptide vaccine in renal cell carcinoma
- (2013) Jens Bedke et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- Renal tumors with clear cells. A review
- (2013) José I. López PATHOLOGY RESEARCH AND PRACTICE
- PD-1 coinhibitory signals: The link between pathogenesis and protection
- (2013) Deanna A. Kulpa et al. SEMINARS IN IMMUNOLOGY
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Divide and conquer: the genetic basis of molecular subclassification of breast cancer
- (2011) Vessela N. Kristensen EMBO Molecular Medicine
- Structure and function of programmed death (PD) molecules
- (2009) A. Folkl et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- A divide-and-conquer strategy to improve diffusion sampling in generalized ensemble simulations
- (2008) Donghong Min et al. JOURNAL OF CHEMICAL PHYSICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now